Fibroid-Driven Anemia: GnRH Antagonist Bridge, Leuprolide, or Straight to Myomectomy
Her anemia is severe enough that a medical bridge and definitive surgery aren't really competing options — the real question is which drug, and for how long, before the operating room.
Odalys R., a 41-year-old woman, has run her own catering business for twelve years, work built around long, physically demanding event days that have become genuinely hard to get through since her periods turned from heavy to what she describes as unmanageable roughly eight months ago — soaking through protection hourly on her worst days, and twice needing to leave a booked event early. Pelvic ultrasound found three fibroids, the largest 7cm, consistent with the bulk symptoms and bleeding pattern she's describing. She has no interest in future fertility and has said directly she wants this resolved, not managed indefinitely.
Her hemoglobin, at 8.9 g/dL, is low enough to make the timeline itself part of the clinical decision, not just the eventual treatment choice. Relugolix combination therapy — a GnRH antagonist paired with built-in estradiol/norethindrone add-back — has real, randomized trial support here: the LIBERTY 1 and 2 trials found 73% and 71% response rates (meaningful bleeding reduction) against 19% and 15% for placebo, with bone mineral density preserved through 52 weeks of continuous use, durability data that a bare GnRH agonist like leuprolide doesn't carry without a separately constructed add-back regimen. The complicating fact is that Odalys has already told the team she wants a defined path to surgery, not an open-ended medical trial — which reframes the drug choice as a preoperative bridging decision, not a long-term management one.
Odalys has already rebooked her calendar around the planned surgical date, well before today's visit confirmed any specific medication or timeline — a fixed date to plan around matters to her more than which specific drug bridges her there, provided it doesn't push the date out further than necessary. Whether a bridge is worth starting at all turns on a date nobody in the room controls: at a hemoglobin of 8.9 the drug's real job is to buy operative safety, and if the surgical slot lands early enough, iron repletion alone may do it. Oral iron alone typically needs six to eight weeks to meaningfully rebuild hemoglobin at this severity, which means the actual surgical date, not the drug's own efficacy profile, is what decides whether a bridging agent gets started today or held in reserve.
Preoperative planning visit
Relugolix combination therapy is the better bridge — the built-in add-back hormones are exactly what prevents the bone loss and severe vasomotor symptoms that make leuprolide hard to tolerate past a few months. LIBERTY 1 and 2 showed 71-73% response rates against 15-19% for placebo with bone density preserved through 52 weeks, real durability data.
If Odalys were planning to stay on medical therapy long-term rather than bridge to surgery, this wouldn't even be a close call — the add-back tolerability advantage would dominate the decision entirely.
Her hemoglobin is 8.9. That's not a number where an open-ended medical trial, however well-tolerated, is the right first move — she needs a fixed timeline to definitive treatment, and she's told us directly that's what she wants. Whichever drug bridges her there, the actual decision that matters most is committing to a surgical date now, not choosing between two medications as if either represents long-term management.
I'd accept a short, defined bridging window either way — my objection isn't to bridging itself, it's to letting the tolerability comparison above obscure that she should have a surgical date on the calendar regardless of which drug she takes in the meantime.
Given a fixed, short preoperative window rather than long-term management, the calculus actually flips back toward leuprolide. What I need before surgery is maximal fibroid-volume reduction, and leuprolide's more complete gonadotropin suppression produces greater shrinkage over a short window than relugolix's partial suppression does — the bone and vasomotor tolerability concern that favors relugolix matters far less over weeks than it does over the years-long courses LIBERTY was actually designed to test.
Agreed: a firm myomectomy date set for three months out, leuprolide started today as the preoperative bridge to maximize fibroid shrinkage before surgery, and oral iron replacement begun immediately to correct her anemia in parallel. All three positions converged once the decision was reframed as preoperative bridging with a fixed surgical endpoint, rather than a choice between two long-term medical management strategies — the tolerability advantage that opened the debate mattered far less once the actual exposure window was measured in weeks.